Aging Clinical and Experimental Research

, Volume 5, Issue 2, pp 123–133

Cognitive decline in the elderly: A double- blind, placebo- controlled multicenter study on efficacy of phosphatidylserine administration

  • Teresa Cenacchi
  • T. Bertoldin
  • C. Farina
  • M. G. Fiori
  • G. Crepaldi
  • C. F. Azzini
  • R. Girardello
  • B. Bagozzi
  • R. Garuti
  • P. Vivaldi
  • G. Belloni
  • A. Bordin
  • M. Durando
  • M. Lo Storto
  • L. Bertoni
  • A. Battistoni
  • C. Cacace
  • P. Arduini
  • A. Bonini
  • M. P. Caramia
  • G. Vaglieri
  • A. Brusomini
  • G. Donà
  • A. March
  • N. Campi
  • P. Cannas
  • F. Casson
  • G. Cavallarin
  • M. Delia
  • G. Cristianini
  • O. Louvier
  • F. Mello
  • R. Fameli
  • N. Urbani de Gheltoff
  • O. De Candia
  • G. Nante
  • C. Cattoni
  • P. L. Forte
  • M. Loreggian
  • A. Targa
  • G. Mansoldo
  • G. Noro
  • A. Meggio
  • F. Pedrazzi
  • F. Bonmartini
  • C. Ruggiano
  • M. Peruzza
  • G. Olivari
  • E. Recaldin
  • C. Bellunato
  • G. Rigo
  • M. Marin
  • L. Marinangeli
  • A. Saracino
  • O. Miceli
  • G. Lovo
  • R. Scarpa
  • L. Battistello
  • E. Tomat
  • B. Bernava
  • P. Olivo
  • G. Verga
  • G. Merli
  • A. M. Zerman
  • R. Crivellaro
  • A. Vozza
  • G. R. Ziliotto
  • V. Favaretto
  • L. Allegro
Original Articles

DOI: 10.1007/BF03324139

Cite this article as:
Cenacchi, T., Bertoldin, T., Farina, C. et al. Aging Clin Exp Res (1993) 5: 123. doi:10.1007/BF03324139

Abstract

This double- blind study assesses the therapeutic efficacy and the safety of oral treatment with phosphatidylserine (BC- PS) vs placebo (300 mg/day for 6 months) in a group of geriatric patients with cognitive impairment. A total of 494 elderly patients (age between 65 and 93 years), with moderate to severe cognitive decline, according to the Mini Mental State Examination and Global DeteriorationScale, were recruited in 23 Geriatric or General Medicine Units in Northeastern Italy. Sixty- nine patients dropped out within the 6- month trial period. Patients were examined just before starting therapy, and 3 and 6 months thereafter. The efficacy of treatment compared to placebo was measured on the basis of changes occurring in behavior and cognitive performance using the Plutchik Geriatric Rating Scale and the Buschke Selective Reminding Test. Statistically significant improvements in the phosphatidylserine- treated group compared to placebo were observed both in terms of behavioral and cognitive parameters. In addition, clinical evaluation and laboratory tests demonstrated that BC- PS was well tolerated. These results are clinically important since the patients were representative of the geriatric population commonly met in clinical practice. (Aging Clin. Exp. Res. 5: 123- 133, 1993).

Keywords

Cognitive decline elderly phosphatidylserine 

Copyright information

© Editrice Kurtis s.r.l. 1993

Authors and Affiliations

  • Teresa Cenacchi
    • 1
  • T. Bertoldin
    • 2
  • C. Farina
    • 3
  • M. G. Fiori
    • 1
  • G. Crepaldi
    • 2
  • C. F. Azzini
    • 4
  • R. Girardello
    • 4
  • B. Bagozzi
    • 5
  • R. Garuti
    • 5
  • P. Vivaldi
    • 5
  • G. Belloni
    • 6
  • A. Bordin
    • 6
  • M. Durando
    • 6
  • M. Lo Storto
    • 6
  • L. Bertoni
    • 7
  • A. Battistoni
    • 7
  • C. Cacace
    • 7
  • P. Arduini
    • 7
  • A. Bonini
    • 8
  • M. P. Caramia
    • 8
  • G. Vaglieri
    • 8
  • A. Brusomini
    • 9
  • G. Donà
    • 9
  • A. March
    • 9
  • N. Campi
    • 10
  • P. Cannas
    • 10
  • F. Casson
    • 11
  • G. Cavallarin
    • 11
  • M. Delia
    • 11
  • G. Cristianini
    • 12
  • O. Louvier
    • 12
  • F. Mello
    • 13
  • R. Fameli
    • 13
  • N. Urbani de Gheltoff
    • 13
  • O. De Candia
    • 14
  • G. Nante
    • 14
  • C. Cattoni
    • 14
  • P. L. Forte
    • 15
  • M. Loreggian
    • 15
  • A. Targa
    • 15
  • G. Mansoldo
    • 16
  • G. Noro
    • 16
  • A. Meggio
    • 16
  • F. Pedrazzi
    • 17
  • F. Bonmartini
    • 17
  • C. Ruggiano
    • 17
  • M. Peruzza
    • 18
  • G. Olivari
    • 18
  • E. Recaldin
    • 19
  • C. Bellunato
    • 19
  • G. Rigo
    • 20
  • M. Marin
    • 20
  • L. Marinangeli
    • 20
  • A. Saracino
    • 21
  • O. Miceli
    • 21
  • G. Lovo
    • 21
  • R. Scarpa
    • 22
  • L. Battistello
    • 22
  • E. Tomat
    • 23
  • B. Bernava
    • 23
  • P. Olivo
    • 23
  • G. Verga
    • 24
  • G. Merli
    • 24
  • A. M. Zerman
    • 25
  • R. Crivellaro
    • 25
  • A. Vozza
    • 25
  • G. R. Ziliotto
    • 26
  • V. Favaretto
    • 26
  • L. Allegro
    • 26
  1. 1.Fidia Research LaboratoriesAbano Terme (Padova)Italy
  2. 2.Institute of Internal MedicineUniversity of PadovaPadova
  3. 3.Third Division of GeriatricsGeriatric HospitalPadovaItaly
  4. 4.Geriatric Dept.HospitalMalo, VI
  5. 5.Geriatric Dept.HospitalTrento
  6. 6.2nd Dept.Geriatric HospitalPadova
  7. 7.2nd Medical Dept.HospitalVerona
  8. 8.3rd Medical Dept.HospitalTrieste
  9. 9.Geriatric Dept.HospitalBolzano
  10. 10.Medical Dept.HospitalTregnago
  11. 11.Medical Dept.HospitalChioggia
  12. 12.Medical Dept.HospitalGorizia
  13. 13.1st Dept.Geriatric HospitalVenezia
  14. 14.3rd Dept.Geriatric HospitalPadova
  15. 15.Geriatric Dept.HospitalRovigo
  16. 16.Geriatric Dept.HospitalRovereto
  17. 17.1st Medical Dept.HospitalVerona
  18. 18.2nd Dept.Geriatric HospitalVenezia
  19. 19.Geriatric Dept.HospitalNegrar
  20. 20.Geriatric Dept.HospitalMarostica, VI
  21. 21.Geriatric Dept.HospitalPiove di Sacco
  22. 22.Geriatric Dept.HospitalChioggia
  23. 23.3rd Medical Dept.Hospital
  24. 24.Geriatric Dept.HospitalLegnago
  25. 25.3rd Medical Dept.HospitalVerona
  26. 26.1st Dept.Geriatric HospitalPadova

Personalised recommendations